Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis

Gao, Peng; Liu, Jue; M, Liu

doi:10.3390/ijerph191912422

Cited by 135 publications

(102 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19,20,21,22 Gompertzian Analysis has found that unlike Gompertzian Lethality, Long COVID occurs at relatively equivalent rates across ages (APPENDIX-FIGURE 40). 23,24 Vaccination has been found to protect against Long COVID , (APPENDIX-FIGURE 41), 25,2627,28 with protection increasing with each additional dose, 29 although the data so are far not sufficient to determine which symptoms are prevented, and most importantly, to what degree pandemic associated excess mortality is reduced, if at all, but vaccination. 30,31 Clearly, this remains a problem of high importance, which should be decipherable by Gompertzian Analysis .…”

Section: Resultsmentioning

confidence: 99%

Counting Cases and Deaths by Age Tells Us About COVID-19’s Infectious and Lethal Components

Michaelson

2023

Preprint

View full text Add to dashboard Cite

Gauging COVID 19 lethality, and how vaccination can reduce that lethality, has been challenging. Here, a new method, Gompertzian Analysis, counting cases and deaths, by age, and displaying them on logarithmic graphs, is outlined, and its first findings presented: FIRST, COVID-19 Gompertzian Lethality (Deaths/Cases) exhibits an ~10,000-fold exponential increase in the chance of death with age, the Gompertzian Force of Mortality, captured by the Gompertz Mortality Equation. SECOND, COVID-19 Pasteurian Infectivity (Cases/Population) occurs at similar rates across ages. THIRD, the same Gompertzian Force of Mortality characterizes other diseases and all-cause mortality, possibly from loss of Mitotic Dilution of toxic compounds due to decline in mitosis. FOURTH, resistance to COVID-19 infectivity and lethality appear to be separate processes. FIFTH, Over the past several years, Gompertzian Lethality, has declined, but not Pasteurian Infectivity. SIXTH, with each variant, Gompertzian Lethality has declined, but not Pasteurian Infectivity. SEVENTH, the unvaccinated have seen a decline in Gompertzian Lethality, less than the vaccinated, ascribable to infection, at the cost of lives lost. EIGHTH, different vaccines have different reductions in Gompertzian Lethality and Pasteurian Infectivity. NINTH, vaccination has reduced Pasteurian Infectivity, but not enough to suppress the pandemic. TENTH, vaccination has reduced Gompertzian Lethality, with sequential vaccination pointing linearly towards zero death after 3 or 4 boosters, without signs of waning. CONCLUSION: Gompertzian Analysis provides new, practical, actionable, information for understanding, and minimizing, the lethal burden of COVID 19 and other diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Counting Cases and Deaths by Age Tells Us About COVID-19’s Infectious and Lethal Components

Michaelson

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The widespread vaccination approach has been a game-changer in reducing the spread as well as the severity of COVID-19 disease in adults [ 151 , 152 ]. Vaccinating pregnant women is a vital strategy to reduce the risk of SARS-CoV-2 transmission to the fetus and newborn baby.…”

Section: Strategies For Preventing Perinatal Covid-19mentioning

confidence: 99%

COVID-19 Disease in Under-5 Children: Current Status and Strategies for Prevention including Vaccination

et al. 2023

View full text Add to dashboard Cite

Since the coronavirus disease (COVID-19) pandemic hit the globe in early 2020, we have steadily gained insight into its pathogenesis; thereby improving surveillance and preventive measures. In contrast to other respiratory viruses, neonates and young children infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have a milder clinical presentation, with only a small proportion needing hospitalization and intensive care support. With the emergence of novel variants and improved testing services, there has been a higher incidence of COVID-19 disease reported among children and neonates. Despite this, the proportion of young children with severe disease has not increased. Key mechanisms that protect young children from severe COVID-19 disease include the placental barrier, differential expression of angiotensin-converting enzyme 2 (ACE-2) receptors, immature immune response, and passive transfer of antibodies via placenta and human milk. Implementing mass vaccination programs has been a major milestone in reducing the global disease burden. However, considering the lower risk of severe COVID-19 illness in young children and the limited evidence about long-term vaccine safety, the risk–benefit balance in children under five years of age is more complex. In this review, we do not support or undermine vaccination of young children but outline current evidence and guidelines, and highlight controversies, knowledge gaps, and ethical issues related to COVID-19 vaccination in young children. Regulatory bodies should consider the individual and community benefits of vaccinating younger children in their local epidemiological setting while planning regional immunization policies.

show abstract

“…In einer rezent publizierten Metaanalyse mit insgesamt über einer Million Patient:innen aus 18 Studien fand man, dass die COVID-Schutzimpfung das Risiko für Long COVID unabhängig vom Zeitpunkt der Impfung verringert [ 35 ]. Das heißt, selbst nach einer bereits abgelaufenen COVID-19-Erkrankung stellt das Impfen danach noch einen Schutzfaktor für Long COVID dar.…”

Section: Die Impfung Schützt Vor Long Covidunclassified

“…Auch in einer größeren retrospektiven Studie mit 14.104 Patientinnen stellte man fest, dass maternale Mortalität und schwerwiegende Schwangerschaftskomplikationen (z. B. hypertensive Störungen, postpartale Blutungen) bei SARS-CoV-2-infizierten Frauen 40 % häufiger auftraten als bei seronegativen Frauen [ 35 ].…”

Section: Risikofaktoren Und Therapie Für Long Covid In Der Schwangers...unclassified

Long COVID – eine neue Herausforderung in der Medizin: Fokus auf Schwangerschaft und Stillzeit

Han

Gyöngyösi

2023

J. Gynäkol. Endokrinol. AT

View full text Add to dashboard Cite

ZusammenfassungLong COVID wurde als eine neue Multiorganerkrankung beschrieben, die bei Frauen häufiger auftritt als bei Männern. Schwangere und stillende Frauen sind eine spezielle Untergruppe von Patienten, die bei einer Long-COVID-Erkrankung zu berücksichtigen sind, da bisher die Datenlage nur gering ausfällt. Menstruationsveränderungen werden häufig während oder nach einer akuten Erkrankung mit dem Coronavirus-2019 (COVID-19) beobachtet. Einige Studien stellen zudem einen Zusammenhang zwischen geringen Veränderungen der Zykluslänge und einer COVID-Impfung dar. Schwangere Frauen, die eine symptomatische Infektion mit dem schweren-akuten-Atemwegssyndrom-Coronavirus Typ 2 (SARS-CoV‑2) hatten, können ein höheres Risiko für Komplikationen in der Schwangerschaft, wie Frühgeburt oder Präeklampsie, haben. Darüber hinaus sind mehr Studien notwendig, um die Auswirkungen einer vertikalen Übertragung zu beurteilen. Das wirksamste Mittel gegen die Pandemie sind die verfügbaren COVID-Impfstoffe, da sie eine Infektion verhindern, aber auch Long-COVID-Symptome lindern können. Impfstoffe haben sich sowohl bei schwangeren als auch bei stillenden Frauen als sicher und wirksam erwiesen. Ziel dieses Artikels ist es, die aktuell verfügbaren Daten zu Long COVID bei schwangeren und stillenden Frauen darzustellen und die Risikofaktoren und therapeutischen Möglichkeiten aufzuzeigen.

show abstract

Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis

Cited by 135 publications

References 47 publications

Counting Cases and Deaths by Age Tells Us About COVID-19’s Infectious and Lethal Components

Counting Cases and Deaths by Age Tells Us About COVID-19’s Infectious and Lethal Components

COVID-19 Disease in Under-5 Children: Current Status and Strategies for Prevention including Vaccination

Long COVID – eine neue Herausforderung in der Medizin: Fokus auf Schwangerschaft und Stillzeit

Contact Info

Product

Resources

About